Supplementary Table 2. Baseline characteristics and final dose of medication of patients with or without dyskinesia

	LID (-)	LID (+)	*p* value
n	51	5	
Male	23 (45.1)	3 (60.0)	0.431
Age of onset (yr)	53.92 ± 9.65	50.00 ± 5.96	0.378
Disease duration (yr)	1.71 ± 1.88	1.80 ± 2.95	0.920
UPDRS I	1.38 ± 1.72	2.75 ± 1.26	0.125
UPDRS II	5.12 ± 4.09	5.75 ± 3.10	0.766
UPDRS III	18.93 ± 8.02	22.60 ± 8.01	0.335
Tremor-dominant subtype*	25 (54.3)	2 (50.0)	0.667
Total LEDD (mg/d)†	605.64 ± 354.01	950.00 ± 254.95	0.039
LED without amantadine and dopamine agonist (mg/d)	248.04 ± 254.55	530.00 ± 189.08	0.020

Data are expressed as *n* (%) or mean ± standard deviation. *calculations of the percentage of the patients with the tremor-dominant subtype and univariate Cox regression analysis were performed after excluding 6 patients with incomplete evaluation, †doses of medication were calculated at the final follow-up. LID: levodopa-induced dyskinesia, UPDRS: Unified Parkinson's Disease Rating Scale, LEDD: levodopa equivalent daily dose, LED: levodopa equivalent dose.